Table 2.
Patient characteristics and expression level of fibronectin, vimentin, and TGF-β.
| Type | ST | 1st Surgery | 2nd Surgery | 3rd Surgery | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Path | FN * | VIM * | TGF-β | Path | FN * | VIM * | TGF-β | Path | FN * | VIM * | TGF-β | ||
| I | 36 | LGA | 1 | 2 | 2 | GBM | 2 | 3 | 3 | ||||
| II | 20 | GBM | 1 | 1 | 1 | GBM | 2 | 2 | 2 | ||||
| III | 41 | GBM | 1 | 0 | 1 | GBM | 2 | 1 | 2 | GBM | 3 | 2 | 3 |
| IV | 15 | GBM | 2 | 2 | 1 | GBM | 3 | 2 | 3 | ||||
| V | alive | GBM | 2 | 1 | 2 | GBM | 3 | 3 | 3 | LGA | 0 | 0 | 0 |
ST: Survival time (months), from diagnosis to death.Path: Pathology; FN: Fibronectin; VIM: Vimentin; TGF-β: Transforming growth factor beta; LGA: Low-grade astrocytoma; GBM: Glioblastoma multiforme. * The expression intensity of IHC staining was assessed by using a semi-quantitative four-grade system: 0, no expression; 1, minimal expression; 2, moderate expression; 3, marked expression with generalized or focal distribution.